BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Trihep's bulging in regard of Ultragenyx speculators; add-on to Mepsevii muscle
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Trihep's bulging in regard of Ultragenyx speculators; add-on to Mepsevii muscle
Feb. 16, 2018
By
Randy Osborne
No Comments
At the WORLD Symposium on lysosomal diseases in San Diego this month, Ultragenyx Pharmaceutical Inc. made a splash with data related to Mepsevii (vestronidase alfa-vjbk, previously UX-003), the company's first drug to win approval.
BioWorld